1. ASCOT-BPLA: Primary and secondary end points
Amlodipine-based regimen
Atenolol-based regimen
Unadjusted hazard ratio (95% CI) p
Primary end point (n)
429
474
0.90
( )
0.1052
Fatal and nonfatal stroke (n)
327
422
0.77
( )
0.0003
Total CV events and procedures (n)
1362
1602
0.84
( )
<0.0001
All-cause mortality (n)
738
820
0.89
( )
0.025
Dahlöf B et al. Lancet Available at:

2. ASCOT-BPLA: Incidence of new-onset diabetes
End point
Amlodipine-based regimen
Atenolol-based regimen
Unadjusted hazard ratio
(95% CI) p
New-onset diabetes
567
799
0.70
( )
<0.0001
Dahlöf B et al. Lancet Available at: